Factors Associated With Recruitment and Screening in the Treatment for Adolescents With Depression Study (TADS)

 Please see end of text for other author affiliations.The opinions and assertions contained in this report are the private views of the authors and are not to be construed as official or as reflecting the views of the National Institute of Mental Health, the National Institutes of Health, or the Department of Health and Human Services.TADS is supported by contract N01 MH80008 from the National Institute of Mental Health to Duke University Medical Center (John S. March, Principal Investigator).Disclosure: Dr. Kratochvil has been a consultant or scientific advisor to Eli Lilly, Shire, Cephalon, Organon, AstraZeneca, Boehringer-Ingelheim, Abbott, and Pfizer; received research support from Abbott, Cephalon, Eli Lilly, Forest, GlaxoSmithKline, and McNeil; served on the speaker's bureau of Eli Lilly; and received study drug for an NIMH-funded study from Lilly. Dr. Silva has been a consultant to Pfizer. Dr. Pathak has received research support from Forest Laboratories. Dr. Weller has been a consultant to and/or received research support from Otsuka, Johnson & Johnson, AstraZeneca, Organon, Pharma, Shire, and GlaxoSmithKline. Dr. March has been a consultant or scientific advisor to Pfizer, Eli Lilly, Wyeth, GlaxoSmithKline, Jazz, and MedAvante; has held stock in MedAvante; received research support from Eli Lilly; received study drug for an NIMH-funded study from Lilly and Pfizer; and is the author of the Multidimensional Anxiety Scale for Children (MASC). The other authors have no financial relationships to disclose.

PII: S0890-8567(09)62168-7

doi:10.1097/CHI.0b013e3180582019

© 2007 The American Academy of Child and Adolescent Psychiatry. Published by Elsevier Inc. All rights reserved.